Pharmacokinetics of escalating doses of oral psilocybin .
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults
Clin Pharmacokinet. 2017 11-Apr;():. 10.1007/s40262-017-0540-6Twelve participants attended 3 separate dosing session, separated by 4 weeks each, of increasing doses of oral psilocybin (0.3, 0.45, 0.6 mg/kg). Participants had blood drawn and urine samples taken at multiple timepoints following administration of psilocybin in order to determine pharmacokinetics of psilocyn. The elimination half life of psilocyn was 3+/-1.1 hours, while an extended elimination phase in some subjects suggest there may be a hydrolysis of the psilocyn glucuronide metabolite.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics